http://orcid.org/0000-0001-6763-1489
Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok & Christopher Wai Kei Lam. (2021) Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy 22:16, pages 2221-2234.
Read now
Read now
Brian Tomlinson, Paul Chan, Yuzhen Zhang & Christopher Wai Kei Lam. (2020) Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opinion on Pharmacotherapy 21:17, pages 2137-2151.
Read now
Read now
Brian Tomlinson, Paul Chan, Yuzhen Zhang, Zhongmin Liu & Christopher Wai Kei Lam. (2020) Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 371-385.
Read now
Read now
M. Ruscica, M. Banach, A. Sahebkar, A. Corsini & C. R. Sirtori. (2019) ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opinion on Pharmacotherapy 20:7, pages 791-803.
Read now
Read now
Marilisa Bove, Arrigo F.G. Cicero & Claudio Borghi. (2019) Emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs 24:1, pages 63-69.
Read now
Read now
Nicola Ferri, Alberto Corsini, Cesare Sirtori & Massimiliano Ruscica. (2017) PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs 26:5, pages 593-602.
Read now
Read now
Articles from other publishers (29)
Hanan B Albackr, Khalid Al Waili, Wael Almahmeed, Mohammad Al Jarallah, Mohammad I Amin, Khalid Alrasadi, Mohammed A. BataisTurky H. AlmigbalAli Youssef, Mohammad Alghamdi, Mohammad Al Shehri, Islam Ahmad, Riham A. ElToukhy, Naji Kholaif, Abdulhalim J. Kinsara, Manal Al-Kindi, Nooshin Barzargani, Magdy Hassan, Shamsa Al Suwaidi, Rajesh Rajan, Hani Altaradi & Khalid F Alhabib. (2023) The Gulf Achievement of Cholesterol Targets in Out-Patients Study
(GULF ACTION): Design, Rationale, and Preliminary Results. Current Vascular Pharmacology 21:4, pages 285-292.
Crossref
Crossref
Erik S.G. Stroes, Harold E. Bays, Maciej Banach, Alberico L. Catapano, P. Barton Duell, Ulrich Laufs, G.B. John Mancini, Kausik K. Ray, William J. Sasiela, Yang Zhang & Antonio M. GottoJr.Jr.. (2023) Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. Atherosclerosis 373, pages 1-9.
Crossref
Crossref
Maciej Banach, Peter E. Penson, Michel Farnier, Zlatko Fras, Gustavs Latkovskis, Ulrich Laufs, Francesco Paneni, Paolo Parini, Matteo Pirro, Željko Reiner, Michal Vrablik & Carlos Escobar. (2023) Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases.
Crossref
Crossref
Serban Maierean, Richard Webb, Maciej Banach & Mohsen Mazidi. (2022) The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events. European Heart Journal Open 2:4.
Crossref
Crossref
Peter E. Penson, Eric Bruckert, David Marais, Željko Reiner, Matteo Pirro, Amirhossein Sahebkar, Gani Bajraktari, Erkin Mirrakhimov, Manfredi Rizzo, Dimitri P. Mikhailidis, Alexandros Sachinidis, Dan Gaita, Gustavs Latkovskis, Mohsen Mazidi, Peter P. Toth, Daniel Pella, Fahad Alnouri, Arman Postadzhiyan, Hung‐I Yeh, G.B. John Mancini, Stephan von Haehling, Maciej Banach, Julio Acosta, Mutaz Al‐Khnifsawi, Fahad Alnouri, Fahma Amar, Atanas G. Atanasov, Gani Bajraktari, Maciej Banach, Sonu Bhaskar, Ibadete Bytyçi, Bojko Bjelakovic, Eric Bruckert, Alberto Cafferata, Richard Ceska, Arrigo F.G. Cicero, Xavier Collet, Magdalena Daccord, Olivier Descamps, Dragan Djuric, Ronen Durst, Marat V. Ezhov, Zlatko Fras, Dan Gaita, Adrian V. Hernandez, Steven R. Jones, Jacek Jozwiak, Nona Kakauridze, Amani Kallel, Niki Katsiki, Amit Khera, Karam Kostner, Raimondas Kubilius, Gustavs Latkovskis, G.B. John Mancini, A. David Marais, Seth S. Martin, Julio Acosta Martinez, Mohsen Mazidi, Dimitri P. Mikhailidis, Erkin Mirrakhimov, Andre R. Miserez, Olena Mitchenko, Natalya P. Mitkovskaya, Patrick M. Moriarty, Seyed Mohammad Nabavi, Devaki Nair, Demosthenes B. Panagiotakos, György Paragh, Daniel Pella, Peter E. Penson, Zaneta Petrulioniene, Matteo Pirro, Arman Postadzhiyan, Raman Puri, Ashraf Reda, Željko Reiner, Dina Radenkovic, Michał Rakowski, Jemaa Riadh, Dimitri Richter, Manfredi Rizzo, Massimiliano Ruscica, Amirhossein Sahebkar, Naveed Sattar, Maria‐Corina Serban, Abdullah M.A. Shehab, Aleksandr B. Shek, Cesare R. Sirtori, Claudia Stefanutti, Tomasz Tomasik, Peter P. Toth, Margus Viigimaa, Pedro Valdivielso, Dragos Vinereanu, Branislav Vohnout, Stephan von Haehling, Michal Vrablik, Nathan D. Wong, Hung‐I Yeh, Jiang Zhisheng & Andreas Zirlik. (2022)
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from
the International Lipid Expert Panel
(ILEP)
. Journal of Cachexia, Sarcopenia and Muscle 13:3, pages 1596-1622.
Crossref
Crossref
Neil C. Henney, Maciej Banach & Peter E. Penson. (2021) RNA Silencing in the Management of Dyslipidemias. Current Atherosclerosis Reports 23:11.
Crossref
Crossref
Peter E. Penson & Maciej Banach. (2021) Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. Nutrients 13:9, pages 2957.
Crossref
Crossref
Andrey V. Susekov, Ludmila A. Korol & Gerald F. Watts. (2021) Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. Cardiovascular Drugs and Therapy 35:4, pages 841-852.
Crossref
Crossref
Chiara Schimmenti, Vincenzo Sucato, Elvira Manzone, Giulia Cancellieri, Francesca Mortillaro, Giuseppina Novo, Alfredo Ruggero Galassi & Fabio Venturella. (2020) Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia. Coronary Artery Disease 32:4, pages 340-344.
Crossref
Crossref
Utsab Bhattacharyya, T. Pooventhiran & Renjith Thomas. (2021) Adsorption of the drug bempedoic acid over different 2D/3D nanosurfaces and enhancement of Raman activity enabling ultrasensitive detection: First principle analysis. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 254, pages 119630.
Crossref
Crossref
Brian Tomlinson, Chen-Hsiu Lin, Paul Chan & Christopher WK Lam. (2021) Personalized medicine in lipid-modifying therapy. Personalized Medicine 18:2, pages 185-203.
Crossref
Crossref
Maciej Banach & Peter E. Penson. (2021) Lipid-lowering therapies: Better together. Atherosclerosis 320, pages 86-88.
Crossref
Crossref
Yayuan Ning, Fei Xu, Rui Xin & Fang Yao. (2020) Palmatine regulates bile acid cycle metabolism and maintains intestinal flora balance to maintain stable intestinal barrier. Life Sciences 262, pages 118405.
Crossref
Crossref
Peter E. Penson & Maciej Banach. (2020) The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. Current Atherosclerosis Reports 22:11.
Crossref
Crossref
Michael S. Kelly, Elisabeth M. Sulaica & Craig J. Beavers. (2020) Role of Bempedoic Acid in Dyslipidemia Management. Journal of Cardiovascular Pharmacology 76:4, pages 376-388.
Crossref
Crossref
Deepak Bhatnagar, Jonathan Schofield & Handrean Soran. 2020. Clinical Molecular Medicine. Clinical Molecular Medicine
245
265
.
Dongdong Wang, Yang Yang, Yingnan Lei, Nikolay T. Tzvetkov, Xingde Liu, Andy Wai Kan Yeung, Suowen Xu & Atanas G. Atanasov. (2019) Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products. Pharmacological Reviews 71:4, pages 596-670.
Crossref
Crossref
Eleni Pappa, Christos V. Rizos, Theodosios D. Filippatos & Moses S. Elisaf. (2019) Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 24:4, pages 315-322.
Crossref
Crossref
Narendra D. Lalwani, Jeffrey C. Hanselman, Diane E. MacDougall, Lulu R. Sterling & Clay T. Cramer. (2019) Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. Journal of Clinical Lipidology 13:4, pages 568-579.
Crossref
Crossref
Maciej Banach & Peter E Penson. (2019) What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. Cardiovascular Research 115:3, pages e26-e31.
Crossref
Crossref
Niki Katsiki & Dimitri P Mikhailidis. (2018) Lipids: a personal view of the past decade. Hormones 17:4, pages 461-478.
Crossref
Crossref
Peter E Penson, D Leann Long, George Howard, Peter P Toth, Paul Muntner, Virginia J Howard, Monica M Safford, Steven R Jones, Seth S Martin, Mohsen Mazidi, Alberico L Catapano & Maciej Banach. (2018) Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. European Heart Journal 39:40, pages 3641-3653.
Crossref
Crossref
Christie M. Ballantyne, Maciej Banach, G.B. John Mancini, Norman E. Lepor, Jeffrey C. Hanselman, Xin Zhao & Lawrence A. Leiter. (2018) Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 277, pages 195-203.
Crossref
Crossref
Maria Mytilinaiou, Ioannis Kyrou, Mike Khan, Dimitris K. Grammatopoulos & Harpal S. Randeva. (2018) Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. Frontiers in Pharmacology 9.
Crossref
Crossref
Peter P. Toth, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Giuseppa Castellino, Manfredi Rizzo & Maciej Banach. (2018) Management of Statin Intolerance in 2018: Still More Questions Than Answers. American Journal of Cardiovascular Drugs 18:3, pages 157-173.
Crossref
Crossref
Maciej Banach & Dimitri P. Mikhailidis. (2018) Statin Intolerance. Cardiology Clinics 36:2, pages 225-231.
Crossref
Crossref
Matteo Pirro, Vanessa Bianconi, Daniela Francisci, Elisabetta Schiaroli, Francesco Bagaglia, Amirhossein Sahebkar & Franco Baldelli. (2017) Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. Journal of Cellular and Molecular Medicine 21:12, pages 3150-3161.
Crossref
Crossref
Anthony S. Wierzbicki. (2017) The challenges of proprotein convertase subtilisin–kexin-9 inhibitors for lipid guidelines and models of care. Current Opinion in Lipidology 28:6, pages 470-476.
Crossref
Crossref
Amirhossein Sahebkar & Maciej Banach. (2017) Response letter: Management of statin-induced myopathies: Much demands and still (almost) empty hands!. Journal of Cachexia, Sarcopenia and Muscle 8:3, pages 514-515.
Crossref
Crossref